Tau and neurodegenerative disease: The story so far

Nature Reviews Neurology

Volumn 12, Issue 1, 2016, Pages 15-27

  Iqbal, Khalid ^a   Liu, Fei ^a   Gong, Cheng Xin ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; DAVUNETIDE; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A PROTEIN; EPOTHILONE D; NOOTROPIC AGENT; P 021; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOTRANSFERASE; TAU PROTEIN; UNCLASSIFIED DRUG; FYN PROTEIN, HUMAN; PROTEIN KINASE FYN;

ALZHEIMER DISEASE; FRONTOTEMPORAL DEMENTIA; GENE; HUMAN; IMMUNOTHERAPY; MAPT GENE; MICROTUBULE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; AGED; ANIMAL; BRAIN; DEGENERATIVE DISEASE; DNA MUTATIONAL ANALYSIS; GENETICS; MEDICAL RESEARCH; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TAUOPATHY;

AGED; ALZHEIMER DISEASE; ANIMALS; BIOMEDICAL RESEARCH; BRAIN; DNA MUTATIONAL ANALYSIS; FRONTOTEMPORAL DEMENTIA; HUMANS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-FYN; TAU PROTEINS; TAUOPATHIES;

EID: 84952718632     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.225     Document Type: Review

References (199)

1. Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., &Kirschner, M. W. A protein factor essential for microtubule assembly. Proc. Natl Acad. Sci. USA 72, 1858-1862 (1975
2. Grundke-Iqbal, I., et al. Abnormal phosphorylation of the microtubule-Associated protein t (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913-4917 (1986
3. Tomlinson, B. E., Blessed, G., &Roth, M. Observations on the brains of demented old people. J. Neurol. Sci. 11, 205-242 (1970
4. Iqbal, K., et al. Protein changes in senile dementia. Brain Res. 77, 337-343 (1974
5. Grundke-Iqbal, I., et al. Microtubule-Associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261, 6084-6089 (1986
6. Iqbal, K., et al. Defective brain microtubule assembly in Alzheimer's disease. Lancet 2, 421-426 (1986
7. Goedert, M., Spillantini, M. G., Potier, M. C., Ulrich, J., &Crowther, R. A. Cloning and sequencing of the cDNA encoding an isoform of microtubule-Associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393-399 (1989
8. Drubin, D. G., &Kirschner, M. W. Tau protein function in living cells. J. Cell Biol. 103, 2739-2746 (1986
9. Lee, G., et al. Phosphorylation of tau by fyn: Implications for Alzheimer's disease. J. Neurosci. 24, 2304-2312 (2004
10. Roberson, E. D., et al. Amyloid â/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700-711 (2011
11. Lindwall, G., &Cole, R. D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259, 5301-5305 (1984
12. Alonso, A. C., Zaidi, T., Grundke-Iqbal, I., &Iqbal, K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl Acad. Sci. USA 91, 5562-5566 (1994
13. Iqbal, K., &Tellez-Nagel, I. Isolation of neurons and glial cells from normal and pathological human brains. Brain Res. 45, 296-301 (1972
14. Cleveland, D. W., Hwo, S. Y., &Kirschner, M. W. Purification of tau, a microtubule-Associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116, 207-225 (1977
15. Grundke-Iqbal, I., Johnson, A. B., Wisniewski, H. M., Terry, R. D., &Iqbal, K. Evidence that Alzheimer neurofibrillary tangles originate from neurotubules. Lancet 1, 578-580 (1979
16. Grundke-Iqbal, I., Johnson, A. B., Terry, R. D., Wisniewski, H. M., &Iqbal, K. Alzheimer neurofibrillary tangles: Antiserum and immunohistological staining. Ann. Neurol. 6, 532-537 (1979
17. Iqbal, K., Zaidi, T., Thompson, C. H., Merz, P. A., &Wisniewski, H. M. Alzheimer paired helical filaments: Bulk isolation, solubility, and protein composition. Acta Neuropathol. 62, 167-177 (1984
18. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., &Wisniewski, H. M. Alzheimer paired helical filaments: Immunochemical identification of polypeptides. Acta Neuropathol. 62, 259-267 (1984
19. Wang, G. P., Grundke-Iqbal, I., Kascsak, R. J., Iqbal, K., &Wisniewski, H. M. Alzheimer neurofibrillary tangles: Monoclonal antibodies to inherent antigen(s). Acta Neuropathol. 62, 268-275 (1984
20. Mehta, P. D., Thal, L., Wisniewski, H. M., Grundke-Iqbal, I., &Iqbal, K. Paired helical filament antigen in CSF. Lancet 2, 35 (1985
21. Braak, H., Braak, E., Grundke-Iqbal, I., &Iqbal, K. Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci. Lett. 65, 351-355 (1986
22. Bancher, C., et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res. 477, 90-99 (1989
23. Braak, H., &Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991
24. Lee, G., Cowan, N., &Kirschner, M. The primary structure and heterogeneity of tau protein from mouse brain. Science 239, 285-288 (1988
25. Himmler, A., Drechsel, D., Kirschner, M. W., &Martin, D. W. Jr. Tau consists of a set of proteins with repeated C terminal microtubule-binding domains and variable N terminal domains. Mol. Cell. Biol. 9, 1381-1388 (1989
26. Kosik, K. S., Crandall, J. E., Mufson, E. J., &Neve, R. L. Tau in situ hybridization in normal and Alzheimer brain: Localization in the somatodendritic compartment. Ann. Neurol. 26, 352-261 (1989
27. Novak, M., Kabat, J., &Wischik, C. M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J. 12, 365-370 (1993
28. Zilka, N., et al. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 580, 3582-3588 (2006
29. Hasegawa, M., et al. Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J. Biol. Chem. 267, 17047-17054 (1992
30. Hanger, D. P., Betts, J. C., Loviny, T. L., Blackstock, W. P., &Anderton, B. H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-Tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71, 2465-2476 (1998
31. Gong, C. X., Singh, T. J., Grundke-Iqbal, I., &Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem. 61, 921-927 (1993
32. Gong, C X., Grundke-Iqbal, I., &Iqbal, K. Dephosphorylation of Alzheimer's Disease Abnormally Phosphorylated Tau by Protein Phosphatase 2A. Neuroscience 61, 765-772 (1994
33. Gong, C. X., et al. Phosphatase activity toward abnormally phosphorylated tau: Decrease in Alzheimer disease brain. J. Neurochem. 65, 732-738 (1995
34. Tanimukai, H., Grundke-Iqbal, I., &Iqbal, K. Up regulation of inhibitors of protein phosphatase 2A in Alzheimer's disease. Am. J. Pathol. 166, 1761-1771 (2005
35. Tsujio, I., et al. Inhibitors of protein phosphatase 2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. FEBS Lett. 579, 363-372 (2005
36. Bolognin, S., et al. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol. 123, 133-151 (2012
37. Basurto-Islas, G., Grundke-Iqbal, I., Tung, Y. C., Liu, F., &Iqbal, K. Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease. J. Biol. Chem. 288, 17495-17507 (2013
38. Wang, X., et al. Alzheimer disease and amyotrophic lateral sclerosis: An etiopathogenic connection. Acta Neuropathol. 127, 243-256 (2014
39. Arif, M., Kazim, S. F., Grundke-Iqbal, I., Garruto, R. M., &Iqbal, K. Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc. Natl Acad. Sci. USA 111, 1144-1149 (2014
40. Khatoon, S., Grundke-Iqbal, I., &Iqbal, K. Brain levels of microtubule-Associated protein tau are elevated in Alzheimer's disease: A radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem. 59, 750-753 (1992
41. Vandermeeren, M., et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61, 1828-1834 (1993
42. Kopke, E., et al. Microtubule-Associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268, 24374-24384 (1993
43. Mandelkow, E., von Bergen, M., Biernat, J., &Mandelkow, E. M. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 17, 83-90 (2007
44. Alonso, A., Zaidi, T., Novak, M., Grundke-Iqbal, I., &Iqbal, K. Hyperphosphorylation induces self-Assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl Acad. Sci. USA 98, 6923-6928 (2001
45. Alonso, A. D., Mederlyova, A., Novak, M., Grundke-Iqbal, I., &Iqbal, K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 279, 34873-34881 (2004
46. Alonso, A. C., Grundke-Iqbal, I., &Iqbal, K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2, 783-787 (1996
47. Clavaguera, F., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913 (2009
48. Clavaguera, F., et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl Acad. Sci. USA 110, 9535-9540 (2013
49. Asuni, A. A., Boutajangout, A., Quartermain, D., &Sigurdsson, E. M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129 (2007
50. Encouraging results of AXON's tau vaccine advance Alzheimer's therapy. AXON Neuroscience [online], http://www.axon-neuroscience.eu/docs/press-release-Axon-post-Aaic.pdf (2015
51. Hutton, M., et al Association of missense and 5 splice-site mutations in tau with the inherited dementia FTDP 17. Nature 393, 702-705 (1998
52. Spillantini, M. G., et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl Acad. Sci. USA 95, 7737-7741 (1998
53. Poorkaj, P., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825 (1998
54. Ghetti, B., et al. Invited review: Frontotemporal dementia caused by microtubule-Associated protein tau gene (MAPT) mutations: A chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol. 41, 24-46 (2015
55. Lu, M., &Kosik, K. S. Competition for microtubule-binding with dual expression of tau missense and splice isoforms. Mol. Biol. Cell 12, 171-184 (2001
56. Sengupta, A., Grundke-Iqbal, I., &Iqbal, K. Regulation of phosphorylation of tau by protein kinases in rat brain. Neurochem. Res. 31, 1473-1480 (2006
57. Ishihara, T., et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751-762 (1999
58. Gftz, J., Chen, F., van Dorpe, J., &Nitsch, R. M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ42 fibrils. Science 293, 1491-1495 (2001
59. Lewis, J., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491 (2001
60. Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., &Ferreira, A. Tau is essential to β amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA 99, 6364-6369 (2002
61. Iqbal, K., et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann. Neurol. 58, 748-757 (2005
62. Maruyama, M., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108 (2013
63. Fodero-Tavoletti, M. T., et al. 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134, 1089-1100 (2011
64. Okamura, N., et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J. Nucl. Med. 54, 1420-1427 (2013
65. Chien, D. T., et al. Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457-468 (2013
66. Chien, D. T., et al. Early clinical PET imaging results with the novel PHF-Tau radioligand [F18]-T808. J. Alzheimers Dis. 38, 171-184 (2014
67. Ksiezak-Reding, H., Liu, W. K., &Yen, S. H. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res. 597, 209-219 (1992
68. Morishima-Kawashima, M., et al. Proline-directed and non-proline-directed phosphorylation of PHF-Tau. J. Biol. Chem. 270, 823-829 (1995
69. Mori, H., Kondo, J., &Ihara, Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235, 1641-1644 (1987
70. Perry, G., Friedman, R., Shaw, G., &Chau, V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl Acad. Sci. USA 84, 3033-3036 (1987
71. Grundke-Iqbal, I., et al. Microtubule-Associated polypeptides tau are altered in Alzheimer paired helical filaments. Brain Res. 464, 43-52 (1988
72. Cripps, D., et al. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys 48, Lys 11, and Lys 6 ubiquitin conjugation. J. Biol. Chem. 281, 10825-10838 (2006
73. Wischik, C. M., et al. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. USA 85, 4884-4888 (1988
74. Gamblin, T. C., et al. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl Acad. Sci. USA 100, 10032-10037 (2003
75. Zhang, Z., et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat. Med. 20, 1254-1262 (2014
76. Ledesma, M. D., Bonay, P., Colaco, C., &Avila, J. Analysis of microtubule-Associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269, 21614-21619 (1994
77. Smith, M. A., et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl Acad. Sci. USA 91, 5710-5714 (1994
78. Wang, J. Z., Grundke-Iqbal, I., &Iqbal, K. Glycosylation of microtubule-Associated protein tau: An abnormal posttranslational modification in Alzheimer's disease. Nat. Med. 2, 871-875 (1996
79. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., &Gong, C. X. O GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 10804-10809 (2004
80. Reynolds, M. R., et al. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies. J. Neurosci. 26, 10636-10645 (2006
81. Odetti, P., et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 59, 393-397 (2000
82. Dorval, V., &Fraser, P. E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and α-synuclein. J. Biol. Chem. 281, 9919-9924 (2006
83. Min, S. W., et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953-966 (2010
84. Cohen, T. J., et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252 (2011
85. Min, S. W., et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 21, 1154-1162 (2015
86. Wang, J. Z., Grundke-Iqbal, I., &Iqbal, K. Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase 2A,-2B and-1. Brain Res. Mol. Brain Res. 38, 200-208 (1996
87. Alonso, A. D., Grundke-Iqbal, I., Barra, H. S., &Iqbal, K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-Associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl Acad. Sci. USA 94, 298-303 (1997
88. Alonso, A. D., et al. Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J. Biol. Chem. 276, 37967-37973 (2001
89. Wang, J. Z., Grundke-Iqbal, I., &Iqbal, K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25, 59-68 (2007
90. Prez, M., Valpuesta, J. M., Medina, M., Montejo de Garcini, E., &Avila, J. Polymerization of tau into filaments in the presence of heparin: The minimal sequence required for tau-Tau interaction. J. Neurochem. 67, 1183-1190 (1996
91. Kontsekova, E., Zilka, N., Kovacech, B., Novak, P., &Novak, M. First in man tau vaccine targeting structural determinants essential for pathological tau-Tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res. Ther. 6, 44 (2014
92. Arnold, C. S., et al. The microtubule-Associated protein tau is extensively modified with O linked N acetylglucosamine. J. Biol. Chem. 271, 28741-28744 (1996
93. Yuzwa, S. A., et al. Mapping O GlcNAc modification sites on tau and generation of a site-specific O GlcNAc tau antibody. Amino Acids 40, 857-868 (2011
94. Liu, F., et al. Reduced O GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132, 1820-1832 (2009
95. Gong, C. X., Liu, F., Grundke-Iqbal, I., &Iqbal, K. Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O GlcNAcylation. J. Alzheimers Dis. 9, 1-12 (2006
96. Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., &Gong, C. X. Brain glucose transporters, O GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J. Neurochem. 111, 242-249 (2009
97. Ishiguro, K., et al. Tau protein kinase I converts normal tau protein into A68 like component of paired helical filaments. J. Biol. Chem. 267, 10897-10901 (1992
98. Arioka, M., et al. Tau protein kinase II is involved in the regulation of the normal phosphorylation state of tau protein. J. Neurochem. 60, 461-468 (1993
99. Liu, F., et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 22, 3224-3233 (2008
100. Woods, Y. L., et al. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Be at Ser539 and the microtubule-Associated protein tau at Thr212: Potential role for DYRK as a glycogen synthase kinase 3 priming kinase. Biochem. J. 355, 609-615 (2001
101. Baudier, J., &Cole, R. D. Interactions between the microtubule-Associated tau proteins and S100b regulate tau phosphorylation by the Ca2+/calmodulin-dependent protein kinase II. J. Biol. Chem. 263, 5876-5883 (1988
102. Ledesma, M. D., Correas, I., Avila, J., &Díaz-Nido, J. Implication of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer's disease. FEBS Lett. 308, 218-224 (1992
103. Singh, T. J., Grundke-Iqbal, I., &Iqbal, K. Differential phosphorylation of human tau isoforms containing three repeats by several protein kinases. Arch. Biochem. Biophys. 328, 43-50 (1996
104. Singh, T. J., Zaidi, T., Grundke-Iqbal, I., &Iqbal, K. Non-proline-dependent protein kinases phosphorylate several sites found in tau from Alzheimer disease brain. Mol. Cell. Biochem. 154, 143-151 (1996
105. Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E. M., &Mandelkow, E. MARK, a novel family of protein kinases that phosphorylate microtubule-Associated proteins and trigger microtubule disruption. Cell 89, 297-308 (1997
106. Sironi, J. J., et al. Ser 262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett. 436, 471-475 (1998
107. Singh, T J., Haque, N., Grundke-Iqbal, I., &Iqbal, K. Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK 3. FEBS Lett. 358, 267-272 (1995
108. Singh, T. J., Zaidi, T., Grundke-Iqbal, I., &Iqbal, K. Modulation of GSK 3 catalyzed phosphorylation of microtubule-Associated protein tau by non-proline-dependent protein kinases. FEBS Lett. 358, 4-8 (1995
109. Sengupta, A., et al. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357, 299-309 (1998
110. Sengupta, A., Wu, Q., Grundke-Iqbal, I., Iqbal, K., &Singh, T. J. Potentiation of GSK 3 catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167, 99-105 (1997
111. Liu, F., et al. PKA modulates GSK 3β-And cdk5 catalyzed phosphorylation of tau in site-And kinase-specific manners. FEBS Lett. 580, 6269-6274 (2006
112. Yamaguchi, H., et al Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 92, 232-241 (1996
113. Pei, J. J., et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797, 267-277 (1998
114. Pei, J. J., et al. Distribution of active glycogen synthase kinase 3beta (GSK 3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58, 1010-1019 (1999
115. Pei, J. J., et al. Localization of active forms of C jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J. Alzheimers Dis. 3, 41-48 (2001
116. Jin, N., et al. Truncation and activation of dual specificity tyrosine phosphorylation-regulated kinase 1A by calpain I: A molecular mechanism linked to tau pathology in Alzheimer disease. J. Biol. Chem. 290, 15219-15237 (2015
117. Jin, N., et al. Truncation and activation of GSK 3â by calpain I: A molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease. Sci. Rep. 5, 8187 (2015
118. Gong, C. X., et al. Phosphorylation of microtubule-Associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J. Biol. Chem. 275, 5535-5544 (2000
119. Bennecib, M., Gong, C. X., Grundke-Iqbal, I., &Iqbal, K. Role of protein phosphatase 2A and-1 in the regulation of GSK 3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 485, 87-93 (2000
120. Liu, F., Grundke-Iqbal, I., Iqbal, K., &Gong, C. X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22, 1942-1950 (2005
121. Iqbal, K., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta 1739, 198-210 (2005
122. Sengupta, A., Novak, M., Grundke-Iqbal, I., &Iqbal, K. Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase 3 at substrate level. FEBS Lett. 580, 5925-5933 (2006
123. Qian, W., &Liu, F. Regulation of alternative splicing of tau exon 10. Neurosci. Bull. 30, 367-377 (2014
124. Virshup, D. M. Protein phosphatase 2A: A panoply of enzymes. Curr. Opin. Cell Biol. 12, 180-185 (2000
125. McCright, B., Brothman, A. R., &Virshup, D. M. Assignment of human protein phosphatase 2A regulatory subunit genes B56á, B56â, B56ã, B56ä, and B56å (PPP2R5A-PPP2R5E), highly expressed in muscle and brain, to chromosome regions 1q41, 11q12, 3p21, 6p21.1, and 7p11.2 p12. Genomics 36, 168-170 (1996
126. McCright, B., &Virshup, D. M. Identification of a new family of protein phosphatase 2A regulatory subunits. J. Biol. Chem. 270, 26123-26128 (1995
127. Chen, J., Martin, B. L., &Brautigan, D. L. Regulation of protein serine-Threonine phosphatase type 2A by tyrosine phosphorylation. Science 257, 1261-1264 (1992
128. Lee, J., &Stock, J. Protein phosphatase 2A catalytic subunit is methyl-esterified at its carboxyl terminus by a novel methyltransferase. J. Biol. Chem. 268, 19192-19195 (1993
129. Lee, J., Chen, Y., Tolstykh, T., &Stock, J. A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc. Natl Acad. Sci. USA 93, 6043-6047 (1996
130. Tolstykh, T., Lee, J., Vafai, S., &Stock, J. B. Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits. EMBO J. 19, 5682-5691 (2000
131. Wu, J., et al. Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. EMBO J. 19, 5672-5681 (2000
132. Longin, S., et al. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic subunit. J. Biol. Chem. 282, 26971-26980 (2007
133. Li, M., Lyon, M. K., &Garcea, R. L. In vitro phosphorylation of the polyomavirus major capsid protein VP1 on serine 66 by casein kinase II. J. Biol. Chem. 270, 26006-26011 (1995
134. Li, M., Makkinje, A., &Damuni, Z Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry 35, 6998-7002 (1996
135. Li, M., Makkinje, A., &Damuni, Z. The myeloid leukemia-Associated protein SET is a potent inhibitor of protein phosphatase 2A. J. Biol. Chem. 271, 11059-11062 (1996
136. Campion, D., et al. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664-670 (1999
137. Corder, E. H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993
138. Guerreiro, R., et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013
139. Jonsson, T., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116 (2013
140. Halfon, S., Patel, S., Vega, F., Zurawski, S., &Zurawski, G. Autocatalytic activation of human legumain at aspartic acid residues. FEBS Lett. 438, 114-118 (1998
141. Li, D. N., Matthews, S. P., Antoniou, A. N., Mazzeo, D., &Watts, C. Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo. J. Biol. Chem. 278, 38980-38990 (2003
142. Liu, Z., et al. Neuroprotective actions of PIKE L by inhibition of SET proteolytic degradation by asparagine endopeptidase. Mol. Cell 29, 665-678 (2008
143. Arnaud, L., et al. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A/SET. FEBS Lett. 585, 2653-2659 (2011
144. Lee, V. M., Goedert, M., &Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001
145. Murch, S. J., Cox, P. A., &Banack, S. A. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc. Natl Acad. Sci. USA 101, 12228-12231 (2004
146. Pablo, J., et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease. Acta Neurol. Scand. 120, 216-225 (2009
147. Liang, Z., et al. Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J. Alzheimers Dis. 13, 295-302 (2008
148. Iqbal, K., Zaidi, T., Bancher, C., &Grundke-Iqbal, I. Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett. 349, 104-108 (1994
149. Alonso, A. D., Li, B., Grundke-Iqbal, I., &Iqbal, K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc. Natl Acad. Sci. USA 23, 8864-8869 (2006
150. Takeda, S., et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat. Commun. 6, 8490 (2015
151. Sanders, D. W., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271-1288 (2014
152. Khan, U. A., et al. Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. Nat. Neurosci. 17, 304-311 (2014
153. de Calignon, A., et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697 (2012
154. Liu, L., et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302 (2012
155. Asai, H., et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584-1593 (2015
156. Reiman, E. M., et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26 (Suppl. 3), 321-329 (2011
157. Moulder, K. L., et al. Dominantly Inherited Alzheimer Network: Facilitating research and clinical trials. Alzheimers Res. Ther. 5, 48 (2013
158. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01760005 (2015
159. Lovestone, S., et al. A Phase II trial of tideglusib in Alzheimer's disease. J. Alzheimers Dis. 45, 75-88 (2015
160. Forlenza, O. V., De Paula, V. J., &Diniz, B. S. Neuroprotective effects of lithium: Implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chem. Neurosci. 5, 443-450 (2014
161. Tariot, P. N., et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry 68, 853-861 (2011
162. Basurto-Islas, G., et al. Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease. Neurobiol. Aging 35, 2701-2712 (2014
163. Kickstein, E., et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl Acad. Sci. USA 107, 21830-21835 (2010
164. van Eersel, J., et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc. Natl Acad. Sci. USA 107, 13888-13893 (2010
165. Yuzwa, S. A., et al. A potent mechanism-inspired O GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat. Chem. Biol. 4, 483-490 (2008
166. Petrucelli, L., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13, 703-714 (2004
167. Dickey, C. A., et al. The high-Affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117, 648-658 (2007
168. Shibuya, Y., et al. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L tau content at the presymptomatic stage. Neurobiol. Aging 36, 2248-2259 (2015
169. Harrington, C. R., et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease. J. Biol. Chem. 290, 10862-10875 (2015
170. Hochgrafe, K., et al. Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-Aggregant human Tau. Acta Neuropathol. Commun. 3, 25 (2015
171. Wischik, C. M., Harrington, C. R., &Storey, J. M. Tau-Aggregation inhibitor therapy for Alzheimer's disease. Biochem. Pharmacol. 88, 529-539 (2014
172. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02245568term=Taurx., &rank=2 (2014
173. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01689246term=Taurx., &rank=3 (2014
174. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01689233?term=Taurx., &rank=4 (2015
175. Congdon, E. E., Gu, J., Sait, H. B., &Sigurdsson, E. M. Antibody uptake into neurons occurs primarily via clathrin-dependent Fc receptor endocytosis and is a prerequisite for acute tau protein clearance. J. Biol. Chem. 288, 35452-35465 (2013
176. Chai, X., et al. Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 286, 34457-34467 (2011
177. Yanamandra, K., et al. Anti-Tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414 (2013
178. Castillo-Carranza, D. L., et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34, 4260-4272 (2014
179. Dai, C. L., et al. Passive immunization targeting the N terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J. Neural Transm. (Vienna) 122, 607-617 (2015
180. Funk, K. E., Mirbaha, H., Jiang, H., Holtzman, D. M., &Diamond, M. I. Distinct therapeutic mechanisms of Tau antibodies: Promoting microglial clearance versus blocking neuronal uptake. J. Biol. Chem. 290, 21652-21662 (2015
181. Pedersen, J. T., &Sigurdsson, E. M. Tau immunotherapy for Alzheimer's disease. Trends Mol. Med. 21, 394-402 (2015
182. Zhang, B., et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl Acad. Sci. USA 102, 227-231 (2005
183. Gozes, I., Schirer, Y., Idan-Feldman, A., David, M., &Furman-Assaf, S. NAP alpha-Aminoisobutyric acid (IsoNAP). J. Mol. Neurosci. 52, 1-9 (2014
184. Li, B., et al. Failure of neuronal maturation in Alzheimer disease dentate gyrus. J. Neuropathol. Exp. Neurol. 67, 78-84 (2008
185. Kazim, S. F., et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 71, 110-130 (2014
186. Blanchard, J., et al. Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg AD mice. Acta Neuropathol. 120, 605-621 (2010
187. Chohan, M. O., et al. Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiol. Aging 32, 1420-1434 (2011
188. Bolognin, S., Buffelli, M., Puolivali, J., &Iqbal, K. Rescue of cognitive-Aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol. Aging 35, 2134-2146 (2014
189. Rosenmann, H., et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63, 1459-1467 (2006
190. Brion, J. P., Couck, A. M., Passareiro, E., &Flament-Durand, J. Neurofibrillary tangles of Alzheimer's disease: An immunohistochemical study. J. Submicrosc. Cytol. 17, 89-96 (1985
191. Delacourte, A., &Defossez, A. Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J. Neurol. Sci. 76, 173-186 (1986
192. Ihara, Y., Nukina, N., Miura, R., &Ogawara, M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem. 99, 1807-1810 (1986
193. Kosik, K. S., Joachim, C. L., &Selkoe, D. J. Microtubule-Associated protein tau (t) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA 83, 4044-4048 (1986
194. Spillantini, M. G., et al. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments. Proc. Natl Acad. Sci. USA 94, 4113-4118 (1997
195. Hong, M., et al Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP 17. Science 282, 1914-1917 (1998
196. Maeda, S., et al. Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease. Neurosci. Res. 54, 197-201 (2006
197. Maeda, S., et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856-3861 (2007
198. Shi, J., et al. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J. Biol. Chem. 283, 28660-28669 (2008
199. Chen, Y., et al. Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg AD mice. Front. Aging Neurosci. 6, 100 (2014